安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- List of 43 Hemophilia A Medications Compared - Drugs. com
Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available
- Hemophilia Therapies - Rare Disease Advisor
Koāte ® (antihemophilic factor [human]), also known as Koāte-DVI, is a human plasma-derived FVIII indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A Initially approved in the US in 1974, the processing methods have been updated over the years to make the product safer from viral contamination
- Acquired Hemophilia Treatment Management - Medscape
Recombinant antihemophilic factor, porcine sequence Historically, porcine factor VIII has provided a good effect A porcine sequence recombinant FVIII (rpFVIII; Obizur) was approved by the US Food and Drug Administration (FDA) in 2014 for treatment of bleeding episodes in adults with acquired hemophilia
- Our Treatments | Sanofi Rare Blood Disorders
ELOCTATE ® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency) Your healthcare provider may give you ELOCTATE when you have surgery
- FDA Approves Novel Treatment for Hemophilia A or B, with or without . . .
Today, the U S Food and Drug Administration approved a novel treatment for hemophilia A or B, with or without factor VIII or IX inhibitors (neutralizing antibodies)
- Approved Treatments for Hemophilia – Hemophilia News Today
The primary treatment for hemophilia is replacement therapy that supplies the clotting factors to hemophilia patients who lack them Other approved treatments include bypassing agents, gene therapies, and nonfactor replacement therapies Alphanate (human antihemophilic factor von Willebrand factor complex) is a factor replacement therapy to
- Know Your Treatment Options | Novoeight® (Antihemophilic Factor . . .
When comparing your hemophilia A treatment choices, you might also consider extended half-life (EHL) Esperoct ® [antihemophilic factor (recombinant), glycopegylated-exei] We start with the existing Novoeight ® molecule and add PEGylation technology to extend the factor’s half-life
- Frequently Asked Questions - content. takeda. com
[Antihemophilic Factor (Recombinant)] and ADYNOVATE® [Antihemophilic Factor (Recombinant), ADVATE and ADYNOVATE are trusted, full-length factor VIII treatment options with established safety and efficacy 1 ADVATE has been proven effective for prophylaxis, on-demand and surgical use in children and adults
|
|
|